{
    "eid": "2-s2.0-85151297119",
    "title": "Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer",
    "cover-date": "2023-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biotechnology",
            "@code": "1305",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Applied Microbiology and Biotechnology",
            "@code": "2402",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "Antitumor",
        "Immuno-oncology",
        "Immunomodulators",
        "Nivolumab",
        "PD-1",
        "Programmed cell death",
        "Protein therapeutics"
    ],
    "authors": [
        "Christine Joy I. Bulaon",
        "Hongyan Sun",
        "Ashwini Malla",
        "Waranyoo Phoolcharoen"
    ],
    "citedby-count": 0,
    "ref-count": 83,
    "ref-list": [
        "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries",
        "Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas",
        "Recent progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications",
        "Photodynamic therapy: targeting cancer biomarkers for the treatment of cancers",
        "It's getting hot in here: targeting cancer stem-like cells with hyperthermia",
        "Targeted destruction of cancer stem cells using multifunctional magnetic nanoparticles that enable combined hyperthermia and chemotherapy",
        "Hormone therapy in breast cancer",
        "Innovative approaches for cancer treatment: current perspectives and new challenges",
        "Advances in cancer immunotherapy 2019 \u2013 latest trends",
        "Cytokines in the treatment of cancer",
        "Development of new immunotherapy treatments in different cancer types",
        "A review of cancer immunotherapy: from the past, to the present, to the future",
        "Introduction on cancer immunology and immunotherapy",
        "Nivolumab: targeting PD-1 to bolster antitumor immunity",
        "Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways",
        "The blockade of immune checkpoints in cancer immunotherapy",
        "Inhibitory B7-family molecules in the tumour microenvironment",
        "Immune evasion in cancer: mechanistic basis and therapeutic strategies",
        "Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma",
        "Immunostimulatory monoclonal antibodies for cancer therapy",
        "Molecular biomarkers of primary and acquired resistance to T-cell-mediated immunotherapy in cancer: landscape, clinical implications, and future directions",
        "Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors",
        "Chapter 6 - lung adenocarcinoma: second-line treatment",
        "Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers",
        "Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor",
        "In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates",
        "Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges",
        "Cancer immunotherapies\u2013and their cost\u2013take center stage at ASCO's 2015 annual meeting",
        "Contributions of the international plant science community to the fight against human infectious diseases \u2013 part 1: epidemic and pandemic diseases",
        "Contributions of the international plant science community to the fight against infectious diseases in humans\u2014Part 2: affordable drugs in edible plants for endemic and re-emerging diseases",
        "Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2",
        "Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana",
        "Expression and immunogenicity assessment of a plant-made immunogen targeting the cytotoxic T-lymphocyte associated antigen-4: a possible approach for cancer immunotherapy",
        "Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: protective efficacy, immunogenicity, safety, and toxicity",
        "Harnessing the potential of plant expression system towards the production of vaccines for the prevention of human papillomavirus and cervical cancer",
        "Monoclonal Antibodies B38 and H4 Produced in Nicotiana benthamiana Neutralize SARS-CoV-2 in vitro",
        "Structural and in vitro functional analyses of novel plant-produced anti-human PD1 antibody",
        "Plant-produced anti-enterovirus 71 (EV71) monoclonal antibody efficiently protects mice against EV71 infection",
        "Nicotiana benthamiana as a transient expression host to produce auxin analogs",
        "Rapid transient expression of functional human vascular endothelial growth factor in Nicotiana benthamiana and characterization of its biological activity",
        "Biotechnological insights on the expression and production of antimicrobial peptides in plants",
        "Plant-produced recombinant SARS-CoV-2 receptor-binding domain; an economical, scalable biomaterial source for COVID-19 diagnosis",
        "Plant molecular farming: much more than medicines",
        "Plant molecular farming: a viable platform for recombinant biopharmaceutical production",
        "Molecular pharming for low and middle income countries",
        "Plant Expression platform for the production of recombinant pharmaceutical proteins",
        "The potential of plants as a system for the development and production of human biologics",
        "Plant molecular farming: a viable platform for recombinant biopharmaceutical production",
        "Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure",
        "Advanced plant-based glycan engineering",
        "Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution",
        "Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy",
        "Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment",
        "Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations",
        "Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma",
        "Restoring function in exhausted CD8 T cells during chronic viral infection",
        "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression",
        "Programmed death ligand-1 expression in non-small cell lung cancer",
        "Distinct cellular mechanisms underlie anti-CTLA-4 and Anti-PD-1 checkpoint blockade",
        "Pembrolizumab versus Ipilimumab in advanced melanoma",
        "Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort",
        "Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study",
        "Immune checkpoint inhibitors of PD-L1 as cancer therapeutics",
        "Anti-PD1/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations",
        "Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates",
        "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer",
        "Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab",
        "PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma",
        "CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for Nivolumab versus Everolimus in advanced renal cell carcinoma",
        "Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial",
        "Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future",
        "Co-inhibitory molecules of the B7\u2013CD28 family in the control of T-cell immunity",
        "Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts",
        "Hazards of diethyl phthalate (DEP) exposure: a systematic review of animal toxicology studies"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "126563806",
            "affilname": "Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126563806",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "126194184",
            "affilname": "Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126194184",
            "affiliation-country": "China"
        }
    ],
    "funding": [
        "National Research Council of Thailand and Baiya Phytopharm Co., Ltd"
    ]
}